Patients with rheumatoid arthritis are at increased risk of serious infections, myocardial infarction, and coronary heart disease, an analysis of Medicare claims data suggests. READ MORE
Higher scores on a multi-biomarker disease activity system are associated with hospital infection, myocardial infarction, and coronary heart disease events in older patients with rheumatoid arthritis.
A myriad of factors including lack of guidelines, wealth of drug options, cost concerns, and varying efficacy make treatment decisions for rheumatoid arthritis a challenge.
A psoriasis drug is now approved to treat psoriatic arthrits in adults.
The prevalence of rheumatic immune-related adverse events in 524 patients with cancer who received immune checkpoint inhibitors was 6.6%, according to a single-center observational study published in Annals of the Rheumatic Diseases.
Research in Review
An analysis of biologics for rheumatoid arthritis showed tocilizumab monotherapy and tocilizumab plus methotrexate were superior to conventional drugs.
Patients with RA previously treated to a first-line TNF drug may experience a better outcome with a non-TNF biologic agent than with a second anti-TNF therapy.
The presence of two cellular biomarkers may help to identify patients with rheumatoid arthritis who will not benefit from rituximab.
There may be little difference between treatment strategies that utilize musculoskeletal ultrasound or disease activity in rheumatoid arthritis measurements.